Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes
Neurogastroenterology & Motility · 2023-02 · 35 (2)
DOI: 10.1111/nmo.14493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 13.11.2022. Verfasst von Elizabeth N Madva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Brain, Neurotransmitter Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background
Little is known about the impact of psychiatric comorbidity on pharmacologic treatment outcomes, including neuromodulators (medications targeting the gut–brain axis), among adult patients with disorders of gut–brain interaction (DGBI). Accordingly, we aimed to examine associations between psychiatric comorbidity and DGBI pharmacologic treatment outcomes.
Methods
In a retrospective study of consecutively referred new patients ( N = 410; ages 18–90; 73% female) to a tertiary neurogastroenterology clinic in 2016 with follow‐up through 2018, relationships between psychiatric illness (any psychiatric illness, anxiety disorders, depressive disorders) and pharmacologic treatment selection (any medication, neuromodulating medication) and treatment outcomes, respectively, were examined using multivariable logistic regression, adjusting for demographics, gastrointestinal (GI) diagnoses, and pre‐existing neuromodulator use. Key Results Anxiety disorders (35%) were the most common psychiatric comorbidity, followed by depressive disorders (29%). Patients with anxiety disorders were more likely to be prescribed a neuromodulator by their gastroenterologist (OR = 1.72 [95% CI 1.10–2.75]) yet less likely to respond to neuromodulators (OR = 0.43 [0.21–0.90]) or any GI medication (OR = 0.24 [0.12–0.50]) in fully adjusted analyses. In contrast, depressive disorders were not associated with neuromodulator prescription or response. Conclusions and Inferences Anxiety disorders are common among patients with DGBI and significantly reduce the likelihood of GI pharmacologic treatment response to any medication prescribed, including neuromodulators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Center for Neurointestinal Health, Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Mt. Sinai Hospital, Psychiatry and Gastroenterology, New York, New York, USA.
ORCID-Profile: Elizabeth N Madva, Kyle Staller, Helen Burton Murray
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
- Harvard Medical School
Zitieren
APA
Madva, E. N., Staller, K., Huffman, J. C., Kuo, B., Garcia-Fischer, I., Atkins, M., Keefer, L., Celano, C. M., & Murray, H. B. (2023). Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes. Neurogastroenterology & Motility, 35(2). https://doi.org/10.1111/nmo.14493
Vancouver
Madva EN, Staller K, Huffman JC, Kuo B, Garcia-Fischer I, Atkins M, et al. Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes. Neurogastroenterology & Motility. 2023;35(2). doi:10.1111/nmo.14493
BibTeX
@article{Madva2023,
author = {Madva, Elizabeth N and Staller, Kyle and Huffman, Jeff C and Kuo, Braden and Garcia-Fischer, Isabelle and Atkins, Micaela and Keefer, Laurie and Celano, Christopher M and Murray, Helen Burton},
title = {Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes},
journal = {Neurogastroenterology & Motility},
year = {2023},
volume = {35},
number = {2},
doi = {10.1111/nmo.14493}
}
EUVIMED